Study record
Leukocyte telomere length and mortality in 64,637 individuals (Rode et al., 2015)
Human observational cohort — biomarker association (contested)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 4 — Human pilot / observational — biomarker
Record verify: source publication identified; see evidence and limitations
| Design | Prospective observational cohort (leukocyte telomere length ↔ mortality association) |
| N | 64637 |
| DOI | 10.1093/jnci/djv074 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. Original eight-page JNCI journal PDF was identity-checked against the publisher record; the preserved file is publicly hosted on nosue.org. |
Five-qualifier claim
| Species / population | 64,637 individuals from the Danish general population (Copenhagen General Population Study / Copenhagen City Heart Study) — an observational cohort. |
| Exposure, route, schedule | No intervention — leukocyte telomere length measured (qPCR) and related to outcomes; this is an association study. |
| Comparator / duration | Prospective cohort with long-term mortality follow-up; genetic (Mendelian-randomization) analyses included. |
| Endpoint / numeric result | In observational analysis, the shortest versus longest leukocyte-telomere decile had adjusted all-cause mortality HR1.40 (95%CI1.25–1.57). Genetic analysis associated200bp shorter telomeres with lower cancer mortality (OR0.86,95%CI0.76–0.96), but not with all-cause mortality. Possible confounding or reverse causation is an interpretation, not a measured causal mediation fraction. |
| What it did NOT establish | This Copenhagen cohort and genetic analysis did not test a telomere-changing intervention. Its measured and genetic associations therefore do not establish whether changing telomere length would improve health or extend human lifespan. This is a limit of this study, not a universal conclusion about every intervention. |
Primary reference
https://doi.org/10.1093/jnci/djv074
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.